UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte

Yifei Chen; Fan Yang; Guojun Zheng; Yanjin Wang; L.-P. Liu; Yushan Yan

doi:10.1186/s12951-026-04202-x

March 11, 2026Journal of NanobiotechnologyOpen Access

UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the role of UBQLN1 in MASH progression and its implications for therapy.
Examined the effects of UBQLN1 inhibition on MASH progression
Analyzed the regulation of SIKE and p38 MAPK pathways in hepatocytes
Developed a targeted delivery system using RBC-EVs for therapeutic applications.
UBQLN1 inhibition significantly reduced MASH progression
Downregulation of the SIKE/p38 MAPK pathway was observed
The RBC-EVs-targeted delivery system shows potential for effective MASH therapy.

Implication

Inhibition of UBQLN1 reduces MASH progression in hepatocytes, suggesting a new delivery system for therapy.

Abstract

These findings establish the UBQLN1-SIKE-p38 MAPK axis as a critical regulatory pathway in MASH pathogenesis and develop an RBC-EVs-targeted delivery system for MASH therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69b4ba1818185d8a39802a5b https://doi.org/10.1186/s12951-026-04202-x

View Full Paper

Ask AI

Bookmark

Share

UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte

Key Points

Implication

Abstract

Discussion

Cite This Study

UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Nanobiotechnology

Keep reading

More related papers

More from Journal of Nanobiotechnology